All > Mci > Glioblastoma Multiforme

Clindamycin Phosphate for Glioblastoma (GBM)

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Glioblastoma (GBM)+2 MoreClindamycin Phosphate - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will test whether using clindamycin and triamcinolone topical lotions can prevent skin-related side effects for people being treated with Tumor Treating Fields for malignant glioma.

Eligible Conditions
  • Glioblastoma (GBM)
  • Skin Toxicities
  • Glioblastoma

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
triamcinolone acetonide extended-release injectable suspension
1
IV Tedizolid Phosphate
1
Known patch test allergens

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: up to 120 days

up to 120 days
Number of patients without grade 2 or higher skin toxicity
skin-related quality of life

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Similar Trials

1
triamcinolone acetonide extended-release injectable suspension
1
IV Tedizolid Phosphate
2
Known patch test allergens

Trial Design

1 Treatment Group

topical clindamycin and triamcinolone
1 of 1

Experimental Treatment

58 Total Participants · 1 Treatment Group

Primary Treatment: Clindamycin Phosphate · No Placebo Group · Phase 2

topical clindamycin and triamcinoloneExperimental Group · 2 Interventions: Triamcinolone Acetonide, Clindamycin Phosphate · Intervention Types: Drug, Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Triamcinolone
FDA approved
Clindamycin
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 120 days

Who is running the clinical trial?

Memorial Sloan Kettering Cancer CenterLead Sponsor
1,834 Previous Clinical Trials
588,305 Total Patients Enrolled
Mario Lacouture, MDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center
6 Previous Clinical Trials
1,774 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 4 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You are able to self-administer topical agents or have another person who can apply the topical agents.
Treatment with TTF should be initiated within 7 days of planned initiation on this trial.
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top